Notice 7 May 2025 compliance, dea, drug enforcement, opioids, healthcare regulation

⚖️DEA Revokes Registration for Improper Controlled Substance Prescribing

The Drug Enforcement Administration (DEA) issued a revocation order for Margaret Dennis, D.M.D., for improper prescribing of controlled substances, citing numerous violations of federal and state laws. The findings include lack of medical justification, inadequate record-keeping, and failure to monitor potential abuse, highlighting significant compliance issues within the healthcare sector.

Learn More
Notice 1 May 2025 regulatory compliance, pharmaceutical industry, dea, controlled substances, drug enforcement

💊Importer of Controlled Substances Application by US Pharmacopeial Convention

United States Pharmacopeial Convention has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 28 Apr 2025 business compliance, dea, controlled substances, pharmaceutical regulation, drug manufacturing

💊DEA Notice on Controlled Substances Application Correction

The Drug Enforcement Administration (DEA) published a document in the Federal Register on March 26, 2025, concerning a notice of application for bulk manufacturer of Controlled Substances. As that document indicated the registrant's incorrect plans for the listed controlled substances.

Learn More
Notice 28 Apr 2025 compliance, regulation, business operations, pharmaceuticals, dea, controlled substances, skalar pharma llc

💊Skalar Pharma LLC's Application for Importing Controlled Substances

Skalar Pharma LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 28 Apr 2025 compliance, manufacturing, pharmaceutical industry, drug regulation, dea, controlled substances

💊Bulk Manufacturer Registration Application by Pisgah Laboratories

Pisgah Laboratories has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 28 Apr 2025 compliance, healthcare, regulations, pharmaceuticals, dea, controlled substances

💊Siemens Healthcare Diagnostics Applies for Controlled Substances Registration

Siemens Healthcare Diagnostics, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 25 Apr 2025 pennsylvania, business compliance, pharmacy regulations, dea, controlled substances, drug enforcement

💊DEA Revokes Registrations of Multiple Pennsylvania Pharmacies

The DEA issued an Order to Show Cause and Immediate Suspension of Registrations to several pharmacies, alleging violations related to the dispensing and recordkeeping of controlled substances. The findings indicate significant discrepancies in record management, endangering public health, and leading to potential revocation of their registration for the sale of drugs.

Learn More
Notice 25 Apr 2025 compliance, regulation, pharmaceutical industry, usa, importation, dea, controlled substances

💊DEA Notice on Royal Emerald Pharmaceuticals' Import Application

Royal Emerald Pharmaceuticals has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 23 Apr 2025 compliance, healthcare, regulation, pharmaceuticals, dea, controlled substances, drug enforcement, business consequences

⚖️DEA Revocation Decision Impacting De Novo Services, LLC

The Drug Enforcement Administration (DEA) has issued an order revoking the registration of De Novo Services, LLC due to substantial violations in managing controlled substances and maintaining proper recordkeeping. The decision underscores the stringent compliance requirements enforced by federal regulations to protect public health and safety, highlighting the consequences of non-adherence.

Learn More
Notice 22 Apr 2025 compliance, healthcare, regulations, registration, dea, business risk, drug enforcement

⚖️DEA Decision on Svetlana Burtman

The Department of Justice's ruling on Svetlana Burtman highlights numerous violations of the Controlled Substances Act, including operating an unregistered practice and failing to maintain adequate records. This decision underscores the rigorous compliance requirements for healthcare providers regarding controlled substances. The ramifications may extend beyond individual practitioners, influencing broader regulatory practices in the healthcare industry.

Learn More